Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing DOI Creative Commons

Suzanne Schrock-Kelley,

Vivienne Souter, Michael J. Hall

et al.

Communications Medicine, Journal Year: 2024, Volume and Issue: 4(1)

Published: Sept. 30, 2024

Language: Английский

Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy DOI
B. Martínez-Castedo, Daniel G. Camblor,

J. Martín-Arana

et al.

Annals of Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

5
Clonal hematopoiesis, cardiovascular disease and cancer treatment-induced cardiotoxicity DOI

Nan Zhang,

Xu Tian, Dong-Kun Sun

et al.

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop DOI
Vincent D. de Jager, Patrizio Giacomini,

Jennifer A. Fairley

et al.

EBioMedicine, Journal Year: 2025, Volume and Issue: 114, P. 105636 - 105636

Published: March 23, 2025

Language: Английский

Citations

0
Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer DOI Creative Commons
Jorge Martín-Arana, Francisco Gimeno-Valiente, Tenna Vesterman Henriksen

et al.

Nature Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Language: Английский

Citations

0
ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients DOI
Marisol Huerta, Jorge Martín-Arana, Francisco Gimeno-Valiente

et al.

Translational research, Journal Year: 2024, Volume and Issue: 271, P. 105 - 115

Published: May 21, 2024

Language: Английский

Citations

1
The modification role and tumor association with a methyltransferase: KMT2C DOI Creative Commons
Yunjuan Jiao,

Yuanhao Lv,

Mingjie Liu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 6, 2024

Histone methylation can affect chromosome structure and binding to other proteins, depending on the type of amino acid being modified number methyl groups added, this modification may promote transcription genes (H3K4me2, H3K4me3, H3K79me3) or reduce (H3K9me2, H3K9me3, H3K27me2, H3K27me3, H4K20me3). In addition, advances in tumor immunotherapy have shown that histone as a protein post-translational is also involved proliferation, activation metabolic reprogramming immune cells microenvironment. These modifications proteins play crucial role regulating escape from tumors immunotherapy. Lysine methyltransferases are important components pathway. methyltransferase 2C (KMT2C), known MLL3, member lysine family, which mediates 3 4 (H3K4), participates many regulates signaling pathways such EMT, p53, Myc, DNA damage repair pathways. Studies KMT2C found it aberrantly expressed diseases, mainly hematological disorders. It inhibit onset progression these diseases. Therefore, serve promising target for certain Here, we provide an overview KMT2C, disease mechanisms, diseases associated with discuss related challenges.

Language: Английский

Citations

0
Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing DOI Creative Commons

Suzanne Schrock-Kelley,

Vivienne Souter, Michael J. Hall

et al.

Communications Medicine, Journal Year: 2024, Volume and Issue: 4(1)

Published: Sept. 30, 2024

Language: Английский

Citations

0